NASDAQ:BIVI NASDAQ:BIVIW

BioVie Inc

Market:

NASDAQ

Price

1.02 USD

Day Change

-24.81%

Market Cap:

$7.69 m

52 weeks high

3.98

52 weeks low

0.82

Filter by article type

Viewing results 1-25 of 75

News

Dow Jones falls from record high as oil rebound weighs on stocks

18 hours, 1 minute ago

News

BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim

1 day, 1 hour ago

Video

BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial

1 day, 2 hours ago

News

BioVie: Long COVID trial fully enrolled – ICYMI

on 05/29/2026

News

BioVie to highlight neuro and liver disease programs in June 2 investor webinar

on 05/27/2026

Video

BioVie completes enrollment in Long COVID trial as need for treatments grows

on 05/26/2026

News

BioVie completes enrollment in Phase 2 Long COVID trial

on 05/26/2026

News

Dow, Nasdaq close lower as Treasury yields hit fresh highs

on 05/19/2026

News

BioVie completes final patient visit in Parkinson's drug trial

on 05/19/2026

News

BioVie CEO shares insights into long COVID trial - ICYMI

on 05/09/2026

Video

BioVie advances long COVID trial, top-line data expected by summer

on 05/04/2026

News

BioVie to host KOL event highlighting Bezisterim's potential in Parkinson's Disease

on 04/27/2026

News

BioVie abstract on Parkinson’s drug accepted for neurology conference

on 04/14/2026

News

BioVie CEO explains Bezisterim Parkinson’s trial results - ICYMI

on 04/11/2026

Video

BioVie targets neuroinflammation and insulin resistance in Parkinson’s treatment approach

on 04/09/2026

BioVie targets Parkinson’s at its source with lead drug bezisterim

on 03/26/2026

News

Dow slides as oil prices hit triple digits amid Iran tensions

on 03/12/2026

News

BioVie to present Parkinson’s study data at AD/PD 2026 conference

on 03/12/2026

News

BioVie to host investor webinar on March 4

on 02/23/2026

News

BioVie highlights bezisterim research at ACP meeting

on 02/12/2026

BioVie could offer first new Parkinson’s therapy in decades

on 02/11/2026

News

BioVie hits enrolment milestone in early Parkinson’s trial, data due later this year

on 01/16/2026

News

BioVie advances lead drug candidates - ICYMI

on 12/20/2025

Video

BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026

on 12/17/2025

News

BioVie secures $13.1M funding from US Department of Defense for Long COVID treatment

on 04/29/2024